posted
Hello together! I am an private investor from germany and new on allstocks.com. I am invested in Macrochem since December last year and I am searching for other investors to exchange opinions about chances and risks of this stock.
I will give You a short overview in the following postings.
Posts: 23 | Registered: Feb 2006
| IP: Logged |
MacroChem Discontinues Research and Product Development Activities, Terminates Substantially all Non-Management Personnel, Will Seek Buyer for Company or its Assets LEXINGTON, Mass., Sept. 1 /PRNewswire-FirstCall/ -- At the direction of its board of directors, MacroChem Corporation (Nasdaq: MCHM) is discontinuing all research and product development activities. The Company will seek to sell the business or its assets. As previously announced, the Company has been evaluating strategic alternatives, such as raising additional capital or a merger or acquisition, a sale of the Company or a sale or licensing of its intellectual property. To date, the Company has been unable to identify a satisfactory strategic alternative.
On August 31, 2005, the Company terminated substantially all its non- management personnel. The Company expects to incur a charge of approximately $350,000 in the quarter ending September 30, 2005 in connection with these terminations and the discontinuation of research and product development activities. The Company is currently discussing with its executive officers the restructuring of the Company's contractual obligations to those officers to reduce expenses.
The Company intends to attempt to sell the business or its intellectual property and other operating assets as soon as possible. There is no assurance that these efforts will be successful or that there will be any assets remaining to be distributed to stockholders. The Company believes that it has sufficient resources to fund expenses for the next three months in connection with its efforts to sell the business or its assets, and has entered into a three month sublease of a limited amount of office space at its current address for this purpose.
In addition to its portfolio of intellectual property and early-stage product candidates, MacroChem has two clinical-stage product candidates containing its patented enhancer, SEPA(R): Opterone(R), a topical cream for male testosterone deficiency, and EcoNail(TM), a SEPA-enhanced antifungal nail lacquer to treat a common and potentially debilitating nail infection known as onychomycosis.
Posts: 23 | Registered: Feb 2006
| IP: Logged |
MacroChem Announces $2.5 Million Private Placement with Institutional Investors Company Stock Begins Trading on OTCBB LEXINGTON, Mass., Dec. 28 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MCHM.OB), announced today that it has raised $2.5 million in gross proceeds from a private placement of its securities to two institutional investors, SCO Capital Partners LLC and Lake End Capital LLC.
In this private placement, MacroChem issued 250 shares of Series C Cumulative Convertible Preferred Stock and six-year warrants to purchase 100,000,000 shares of the Company's common stock at an exercise price of $0.03 per share.
The Series C Preferred Stock has a liquidation value of $10,000 per share and is entitled to a dividend of 10% per annum, payable in shares of MacroChem common stock at the Company's option. The Series C Preferred Stock acquired by the investors is convertible into 100,000,000 shares of common stock and the holders of the Series C Preferred Stock vote on an as-converted basis with the holders of MacroChem common stock, and therefore hold approximately 70.5% of the voting power of the Company's outstanding securities. Assuming the conversion of all of their shares of Series C Convertible Preferred Stock, the investors would hold approximately 70.5% of the outstanding common stock of the Company. Assuming both the conversion of the Series C Preferred Stock and the exercise of all of the warrants acquired by the investors, the investors would hold approximately 83% of the outstanding common stock of the Company. Consequently, the investors have acquired control of the Company.
'This private placement gives our Company the opportunity to maintain limited operations while we reprioritize our technologies, redirect our strategic focus and consider strategic alternatives for our products and technologies,' stated Robert J. DeLuccia, President and Chief Executive Officer of MacroChem.
As part of this private placement, the Company has agreed to effect, by January 2, 2006, a 1 for 7 reverse stock split of its common stock approved by the Company's stockholders at its Annual Meeting of Stockholders on June 14, 2005. In addition, MacroChem also agreed to effect an additional 1 for 6 reverse split of its common stock as promptly as practicable. The investors have submitted written consents approving this 1 for 6 stock split, which is expected to become effective 20 days after the Company sends an information statement to its stockholders.
Under the terms of the Purchase Agreement executed in connection with the private placement, for as long as at least 20% of the shares of Series C Preferred Stock issued remain outstanding, SCO Capital Partners LLC has the right to designate two individuals to serve on MacroChem's board of directors.
The Purchase Agreement prohibits the Company from taking certain actions without the approval of a majority of its board of directors, which majority must include at least one of the SCO director designees, until the earlier of March 31, 2006 and additional closings under the Purchase Agreement in which the Company receives gross proceeds of at least $3.5 million.
On September 1, 2005, MacroChem had announced that it was discontinuing its research and development activities and was seeking to sell its business. The funds raised in this private placement will allow the Company to maintain limited operations and evaluate strategic alternatives for its business. There can be no assurance, however, that there will be any additional closings under the Purchase Agreement or that the Company will be able to raise any additional capital. Until the Company is able to raise additional capital, if at all, its operations will be significantly limited.
SCO Securities LLC, an affiliate of SCO Capital Partners LLC, acted as placement agent in connection with the private placement.
The securities offered and sold to the investors in the private placement have not been registered under the Securities Act of 1933, as amended (the 'Securities Act') and were sold in reliance upon the exemption from securities registration afforded by Regulation D under the Securities Act. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.
MacroChem Begins Trading on Over-The-Counter Bulletin Board
On December 22, 2005, MacroChem's common stock began trading on the Over- The-Counter Market on the NASD Electronic Bulletin Board (OTCBB) under the symbol 'MCHM.OB.' The OTCBB is a regulated quotation service that displays real-time quotes, last-sale prices and volume information in over-the-counter (OTC) equity securities. OTCBB securities are traded by a community of market makers that enter quotes and trade reports. Quotations and trading information can still be accessed via websites such as Yahoo! and other quotation services or through a securities broker.
Posts: 23 | Registered: Feb 2006
| IP: Logged |
MacroChem Announces Reverse Stock Split and Appointment of Two New Directors Company Stock Will Continue to Trade on OTCBB under New Ticker Symbol 'MCMP.OB' LEXINGTON, Mass., Jan. 5 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MCMP.OB), announced today that a one-for-seven reverse split of the Company's common stock became effective as of the close of business on December 30, 2005. As a result of the reverse split, MacroChem stockholders at the close of business on December 30, 2005 will receive one share of MacroChem common stock for every seven shares they currently own, and cash payments will be made in lieu of fractional shares to the extent that an individual's holdings are not evenly divisible by seven. American Stock Transfer and Trust Company will serve as the exchange agent in connection with the reverse split and will be mailing instructions to all record holders explaining the process for obtaining new stock certificates. Post-split trading of MacroChem shares on the Over-The-Counter Market on the NASD Electronic Bulletin Board (OTCBB) began on January 3, 2006 under the new ticker symbol 'MCMP.OB.'
Additional information about the reverse stock split is available in MacroChem's definitive proxy statement filed with the Securities and Exchange Commission on May 16, 2005.
MacroChem also announced the appointment of Jeffrey B. Davis and Howard S. Fischer to its board of directors. Both Mr. Davis and Mr. Fischer were designated to serve on MacroChem's board of directors by SCO Capital Partners LLC under the terms of the purchase agreement executed in connection with the previously announced $2.5 million private placement of the Company's Series C cumulative convertible preferred stock and warrants to purchase shares of the Company's common stock.
Mr. Davis (age 42) is president of SCO Securities LLC. He served as senior vice president and chief financial officer of HemaSure, Inc., a publicly traded development stage healthcare technology company. Prior to that, he was vice president, corporate finance, at Deutsche Morgan Grenfell, both in the U.S. and Europe. He also served in senior marketing and product management positions at AT&T Bell Laboratories, where he was also a member of the technical staff. Prior to that, he was involved in marketing and product management at Philips Medical Systems North America. Mr. Davis served previously on the board of Bioenvision, Inc. and currently is a member of the board of directors of Virium Pharmaceuticals, Inc., a private biotechnology company. Mr. Davis holds a BS in biomedical engineering from Boston University and an MBA degree from the Wharton School, University of Pennsylvania.
Mr. Fischer (age 43) is a Managing Director of SCO Securities LLC. Prior to that, he was an investment manager and research analyst for Silverback Asset Management's life sciences fund. Before joining Silverback, he was President of an independent healthcare advisory business, providing consulting services to a number of venture capital firms and their portfolio companies, private equity groups and public and private corporations; in addition, he served as a valuation expert in arbitration proceedings. Mr. Fischer was previously an Executive Director at UBS/PaineWebber Global Healthcare Investment Banking and a Director at Prudential Securities Healthcare Investment Banking. He began his investment banking career at Furman Selz LLC. Mr. Fischer holds an MBA from the University of Chicago's Graduate School of Business and a BS degree from the Wharton School, University of Pennsylvania.
Posts: 23 | Registered: Feb 2006
| IP: Logged |
posted
So when You look at the pipeline an the new investor an investment may be a great chance! No investor would pay $2.5 million if he wouldn´t see a great opportunity to increase his money!
Is anyone else here invested? Are there other opinions?
The pipeline: "In addition to its portfolio of intellectual property and early-stage product candidates, MacroChem has two clinical-stage product candidates containing its patented enhancer, SEPA(R): Opterone(R), a topical cream for male testosterone deficiency, and EcoNail(TM), a SEPA-enhanced antifungal nail lacquer to treat a common and potentially debilitating nail infection known as onychomycosis."
Posts: 23 | Registered: Feb 2006
| IP: Logged |
In the second one Macrochem is mentioned beside other companies:
The Drug Market for Sexual Disorders is Worth Around US$3.8 Billion, and It Expected to Increase by 74% to US$6.6 Billion By 2012 1/24/2006 12:15:00 PM EST
Research and Markets (http://www.researchandmarkets.com/reports/c31361) has announced the addition of the Spectra Intelligence report: The World Market For Sexual Disorders, 2005-2012: Traversing New Frontiers in Sexual Chemistry to their offering.
The sexual disorder pharmacotherapy market is dominated by drugs indicated for erectile dysfunction which commands an estimated 78% of the total sexual disorder market valued at US$3 billion. Significant market opportunities are evident for the expansion of androgenic therapies to treat sexual disorders in new population groups such as in women with hypoactive sexual desire disorder and in male andropause. Furthermore, new drugs are on course to redefine the landscape of sexual medicine by offering novel therapies for premature ejaculation and specific desire-arousal disorders.
Emerging drug treatments targeting the unmet needs of women with sexual disorders are poised to revolutionize the market for sexual dysfunction, and Spectra predicts that the female sexual dysfunction sector may outperform those therapies indicated for male sexual disorders within a decade of availability. However, as a relatively young and controversial therapy area, new drugs for sexual disorders are subject to intense regulatory scrutiny and navigating through the drug approval process is challenging particularly for new sexual disorder indications, which is evident from recent market authorization setbacks for Proctor & Gamble's Intrinsa for female hypoactive sexual desire disorder and Johnson & Johnson/Alza's Dapoxetine for premature ejaculation. However, in this report, The World Market for Sexual Disorders, 2005-2012: Traversing New Frontiers in Sexual Medicine, the reader will be introduced to a specialty pharmaceutical market that is transitioning to a dynamic, high-value therapy area estimated to exceed US$6.6 billion by 2012.
The report provides a detailed analysis of the sexual disorders therapy area to include insights for product extension and reformulation, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also highlighted showing products from preclinical to premarket authorization phases of development, with promising agents further discussed from commercial and drug development perspectives. Therapy area forecasting and illustrative market data and analysis is also presented to offer insights into potential top-performing products. Therapy area forecasting to 2020 also enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.
Objectives of the Report
The objectives of this report are to provide an in-depth analysis of the global sexual disorders therapy market. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. It is hoped that the reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.
REPORT HIGHLIGHTS AND KEY FINDINGS
-- The current market for drugs to treat sexual disorders is estimated at US$3.8 billion, which is forecast to increase 74% to US$6.6 billion by 2012
-- Critical analysis of marketed sexual dysfunction drugs related to erectile dysfunction and androgen deficiency
-- Analysis of over 20 key marketed and pipeline products and inclusion of 43 R&D candidates identified in preclinical to clinical stages of development
-- Sales estimates (US$) to 2012 for leading products
-- Strategic insights for life-cycle optimization and product development
-- Commercial evaluation of leading sexual disorder pharmacotherapies
-- Trend analysis of industry events and activities over past 2 years
-- Detailed R&D themes and clusters by therapy area
-- Data generation on sector and market values between 2004 and 2012 and therapy area forecasts by 2020 (US$)
-- High revenue-yielding prospects identified with projected sales estimations
-- R&D pipeline positioning for novel candidates
-- Market insights for product development and drug promotion
**Please note this report is delivered in pdf format which cannot be printed. For further information on ordering a pdf version which can be printed, please click enquire before buying
Topics Covered
-- List of Tables
-- List of Figures
-- Executive Summary
-- Objectives of the Report
-- Research Methodology
-- Chapter 1 Introduction to Sexual Disorders
-- Chapter 2 The Sexual Disorders Pharmacotherapy Market
-- Chapter 3 Drugs in Research and Development
-- Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining
posted
Yesterday came in a little bit more volume. When there are "bigger" buys the price goes up very fast. But then the stock was put down with little sells.
I expect news about Macrochem´s future very soon. And if they are good, we will see the Dollar very fast! And I do expect good news. Because I can´t believe that someone invests a lot of money ($2.5 million) in nothing!
The actual Market Cap is only 1,562,000 !
Posts: 23 | Registered: Feb 2006
| IP: Logged |
MacroChem Announces Reverse Stock Split Friday February 10, 9:24 am ET Company Stock to Trade Under New Ticker Symbol 'MACM.OB'
LEXINGTON, Mass., Feb. 10 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM.OB - News), today announced a one-for-six reverse split of the Company's common stock, effective as of the close of business February 9, 2006. As a result of the reverse split, holders of MacroChem shares will receive one share of MacroChem common stock for every six shares they currently own, and a cash payment will be made in lieu of fractional shares to the extent that an individual's holdings are not evenly divisible by six. American Stock Transfer and Trust Company will serve as the exchange agent in connection with the reverse split and will be mailing instructions to all record holders explaining the process for obtaining new stock certificates. Post-split trading of MacroChem shares on the Over-The-Counter Market on the NASD Electronic Bulletin Board (OTCBB) begins on February 10, 2006 under the new ticker symbol "MACM.OB."
MacroChem Corporation is a specialty pharmaceutical company with two clinical development stage products containing our patented enhancer, SEPA®: EcoNail(TM), to treat fungal infection of the nail and Opterone®, to treat male hypogonadism. In addition to our SEPA technology, we are also evaluating applications for MacroDerm(TM), our patented series of polymers that impede penetration of active ingredients through the skin.
Additional information about the reverse stock split is available in MacroChem's definitive information statement filed with the Securities and Exchange Commission on January 17, 2006.
Forward-Looking Statements
With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.comPosts: 23 | Registered: Feb 2006
| IP: Logged |
MacroChem Raises Additional $5.75 Million in Second Closing of Private Placement with Institutional Investors Brings Total Amount Raised to $8.25 Million LEXINGTON, Mass., Feb. 13 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM.OB), announced today that it has completed the second closing of a private placement of its securities to institutional investors for approximately $5.75 million in gross proceeds. The transaction represents the second and final closing of a private placement that was first announced on December 28, 2005. In the first closing, which occurred on December 23, 2005, the Company raised $2.5 million in gross proceeds, bringing the total aggregate gross proceeds for the two closings to approximately $8.25 million. Terms and conditions of the second closing were substantially the same as those in the first closing.
SCO Securities LLC acted as the exclusive placement agent, with its affiliate SCO Capital Partners LLC serving as lead investor in the private placement. Other institutional investors included: Perceptive Life Sciences, DAC Fonds, Midsouth Investors Fund LP, Quogue Capital LLC and Iroquois Master Fund Ltd.
'I am very pleased with the confidence and support that this excellent group of investors has shown in our Company by participating in this financing,' stated Robert J. DeLuccia, President and Chief Executive Officer of MacroChem. 'These additional funds provide a recapitalization and restructuring opportunity for our Company and provide a substantive foundation to leverage our products and technologies. We are currently prioritizing our portfolio of products and technologies so we can focus our resources in the most efficient way to advance our lead product candidate to its next value- creating milestone as rapidly as possible.'
References to share amounts and prices in this release reflect adjustments for the 1 for 6 reverse split of the Company's common stock, which was effected as of the close of business on February 9, 2006. Under the terms of the financing, MacroChem issued an aggregate of approximately 825 shares of Series C Cumulative Convertible Preferred Stock and six-year warrants to purchase an aggregate of 7,861,912 shares of the Company's common stock at an exercise price of $1.26 per share. Of this amount, 250 shares of Series C Cumulative Convertible Preferred Stock and six-year warrants to purchase 2,380,951 shares of the Company's common stock at an exercise price of $1.26 per share were issued in the first closing, and approximately 575 shares of Series C Cumulative Convertible Preferred Stock and six-year warrants to purchase 5,480,961 shares of the Company's common stock at an exercise price of $1.26 per share were issued in the second closing.
The securities offered and sold to the investors in the private placement have not been registered under the Securities Act of 1933, as amended (the 'Securities Act') and were sold in reliance upon the exemption from securities registration afforded by Regulation D under the Securities Act. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.
About MacroChem
MacroChem Corporation is a specialty pharmaceutical company with two clinical development stage products containing our patented enhancer, SEPA(R): EcoNail(TM), to treat fungal infection of the nail and Opterone(R), to treat male hypogonadism. In addition to our SEPA technology, we are also evaluating applications for MacroDerm(TM), our patented series of polymers that impede penetration of active ingredients through the skin.
Forward-Looking Statements
With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled 'Risk Factors' in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com
And yesterday was the first day with high volume since a long time!
+9.33%
Remember the words of the President and Chief Executive Officer of MacroChem: ´We are currently prioritizing our portfolio of products and technologies so we can focus our resources in the most efficient way to advance our lead product candidate to its next value- creating milestone as rapidly as possible.'
When they announce their product candidate Macrochem will get a lot attention - and then I think we can be very happy about owning Macrochem shares!
Posts: 23 | Registered: Feb 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
